Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome

BACKGROUND & AIMS: Options for the prevention of short-bowel syndrome–associated liver disease (SBS-ALDs) are limited and often ineffective. The farnesoid X receptor (FXR) is a newly emerging pharmaceutical target and FXR agonists have been shown to ameliorate cholestasis and metabolic disorders...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Mol Gastroenterol Hepatol
Main Authors: Pereira-Fantini, Prue M., Lapthorne, Susan, Gahan, Cormac G.M., Joyce, Susan A., Charles, Jenny, Fuller, Peter J., Bines, Julie E.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5439235/
https://ncbi.nlm.nih.gov/pubmed/28560290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcmgh.2017.02.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados